933.1000 0.25 (0.03%)
NSE Aug 08, 2025 15:31 PM
Volume: 68,143
 

933.10
0.03%
Dolat Capital
Suven Pharma reported soft 2Q. Revenues declined 13% YoY (flattish QoQ) with EBITDA margins at 41% (down 500bps YoY and 600bps QoQ). Lower revenues from specialty chemicals segment impacted margins. Further, lower profit share from Rising Pharma also impacted profits (down 20% YoY and QoQ). Nonetheless, management reiterated its guidance of 15% growth in top-line and 15-20% growth in bottom-line with EBITDA margins at 40%+ for FY21. This implies a robust 2H. Suven is on track in launching molecules (two in specialty chemicals over FY21-22 and one in pharma) in...
Promoters have increased holdings from 50.10% to 66.41% in Jun 2025 qtr.
More from Cohance Lifesciences Ltd.
Recommended